Polypill works and patients like it: expert

The first large-scale analysis of three clinical trials, presented at the World Congress of Cardiology in Melbourne last week, showed that patients taking the tablet were significantly more likely to be adherent to therapy after one year compared to those taking multiple medications.

The analysis of the IMPACT trial in New Zealand, the UMPIRE trial in Western Europe and India, and the Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) study in Australia, included data on more than 31,000 patients.

Dr Ruth Webster, trial coordinator at the George Institute, said patients also achieved significantly lower LDL